Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
- Nature Careers
- Leibniz
- DAAD
- Technical University of Munich
- Forschungszentrum Jülich
- Charité – Universitätsmedizin Berlin
- Free University of Berlin
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- Max Planck Institute of Immunobiology and Epigenetics, Freiburg
- Technische Universität Dresden
- University of Cologne
- University of Tübingen
- 2 more »
- « less
-
Field
-
cancer cell survival, immune evasion, and proliferation. Metabolic studies will be a major component of this work, with an emphasis on uncovering how TME-associated metabolic changes regulate gene
-
candidate will join an exciting research program exploring a newly emerging paradigm in immunology: mitochondrial transfer and synthetic organelle therapy. Using newly developed genetically engineered mouse
-
. Because of the specific structure of the inference problems occurring in metabolic models, direct application of these MCMC algorithms is, however, not possible. In this project, you will bring MCMC methods
-
of engineers, microbiologists, and biotechnologists. Our group pioneers biotechnological platforms that connect microbial processes to future industrial applications while uncovering fundamental principles
-
investigates how cells control their metabolism on a large scale. With a focus on yeast, we use functional genomics and develop advanced mass spectrometry to study how genes and metabolic pathways interact. Our
-
senescence programs can bias myeloid differentiation and survival, rewire metabolic set-points, and “pre-tune” signaling thresholds, leading to exaggerated inflammatory outputs or blunted immunological
-
mentorship in the career development of the student. The program language is English. We offer: a highly international research environment and state-of-the-art technology four years of full funding through
-
international and dynamic team of engineers, microbiologists, and biotechnologists. Our group pioneers biotechnological platforms that connect microbial processes to future industrial applications while
-
of human diseases (e.g., Zhang et al., Nature Microbiology, 2025; Li et al., Nature Metabolism, 2024; Ni et al., Cell Metabolism, 2023; Leung et al., Science Translational Medicine, 2022; Seelbinder et al
-
diseases (e.g., Zhang et al., Nature Microbiology, 2025; Li et al., Nature Metabolism, 2024; Ni et al., Cell Metabolism, 2023; Leung et al., Science Translational Medicine, 2022; Seelbinder et al., Nature